REFERENCES
- Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estévez R, Canton E, Gobernado M. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioterap 2006; 19: 252–247.
- Blaser J. Interactions of antimicrobial combinations in vitro: the rela-tivity of synergism. Scan J Infect Dis Suppl 1990; 74: 71–79.
- Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone suscepti-bility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J An-timicrob Chemother 2006; 57: 279–287.
- Schito GC, Debbia EA, Pesce A. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative sur-veillance study (1992-1993). The Alexander Project Collaborative Group. J Antimicrob Chemother 1996; 38 (Suppl A): 97-106.
- Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129–1140.
- Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58: 256–265.
- Strukova EN, Smimova MV, Vostrov SN, Portnoy YA, Dovzhenko SA, Kobrin MB et al. Anti-staphylococcal effects of telavancin and vancomycin in in vitro simulations of the antibiotic pharmacokinetics. Clin Microbiol n-timicrob Chemother. 2009; 11: 56–65. ( Rus)
- Smirnova MV, Vostrov SN, Strukova EN, Dovzhenko SA, Kobrin MB, Portnoy YA et al. The impact of duration of antibiotic exposure onbacterialresistance predictions using in vitro dynamic models. J Antimicrob Chemother 2009; 64: 815–820.
- Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. Inter- and infra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42: 659–665.
- Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15 (Suppl A): 131-137.
- Firsov AA, Chernykh VM, Navashin SM. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob Agents Chemother 1990; 34: 1312–1317.
- Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. An-timicrob. Agents Chemother 1997; 41: 1281–1287.
- Zinner SH, Gilbert D, Lubenko IY, Greer K, Firsov AA. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: pro-tective effect of doxycycline. J Antimicrob Chemother 2008; 61: 629–663.
- Smimova M, Alferova I, Lubenko I, Portnoy Y, Zinner S, Firsov A. Bacterial strain-independent pharmacodynamics of linezolid/doxycycline combinations with Staphylococcus aureus: 5-day simulations using an in vitro dynamic model. Clin Microbiol Infect 2006; 12 (Suppl. 4): Abstract P1519.
- Oberdisse E, Hackenthal E, Kuschinsky K. Pharmakologie und Toxikologie. 3. Auflage. Berlin, Heidelberg, New York: Springer-Verlag, 2002.
- Tallarida RJ. An overview of drug combination analysis with isobolo-grams. J Pharm Exp Ther 2006; 319: 1–7.
- Firsov A, Smirnova M, Strukova E, Portnoy Y, Zinner S. Staphylo-coccal resistance studies using susceptible organisms supplemented with their resistant mutants: combined treatment with linezolid (LZD) and gentamicin (GEN) simulated in an in vitro dynamic model. 48th Intersci Conf Antimicrob Agents and Chemother 2010, Abstract A1-006.